1
|
Bolte KN, Wealing JC, Revill AL. Arginine vasopressin potentiates inspiratory bursting in hypoglossal motoneurons of neonatal mice. Respir Physiol Neurobiol 2023; 314:104087. [PMID: 37269889 PMCID: PMC10443434 DOI: 10.1016/j.resp.2023.104087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 05/24/2023] [Accepted: 05/26/2023] [Indexed: 06/05/2023]
Abstract
Vasopressin (AVP) acts as a neurotransmitter and its activity can potentiate respiratory activity. Hypoglossal (XII) motoneurons that innervate the tongue express V1a vasopressin receptors, which are excitatory. Therefore, we hypothesized that V1a receptor activation at XII motoneurons would potentiate inspiratory bursting. We developed this study to determine whether AVP can potentiate inspiratory bursting in rhythmic medullary slice preparations in neonatal (postnatal, P0-5) mice. Bath or local application of AVP potentiated inspiratory bursting compared to baseline XII inspiratory burst amplitude. Antagonizing V1a receptors revealed significant attenuation of the AVP-mediated potentiation of inspiratory bursting, while antagonism of oxytocin receptors (at which AVP has similar binding affinity) revealed a trend to attenuate AVP-mediated potentiation of inspiratory bursting. Finally, we discovered that the AVP-mediated potentiation of inspiratory bursting increases significantly with postnatal maturation from P0-5. Overall, these data support that AVP potentiates inspiratory bursting directly at XII motoneurons.
Collapse
Affiliation(s)
- K N Bolte
- Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, United States
| | - J C Wealing
- Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, United States
| | - A L Revill
- Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, United States; Department of Physiology, College of Graduate Studies, Midwestern University, Glendale, AZ, United States.
| |
Collapse
|
2
|
Lv J, Hua SJ, Wu XF, Ding YJ, Zhang CL, Sun FJ. REMOVED: Antidiuretic hormone associates with the cognitive memory in small-cell lung cancer patients. CURRENT RESEARCH IN BEHAVIORAL SCIENCES 2021. [DOI: 10.1016/j.crbeha.2021.100061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
3
|
Abstract
The neurohypophyseal hormone oxytocin (OT) and related modulators of the oxytocin receptor (OTR) have been the subject of intensive research for nearly seven decades. Despite having rather poor drug-like properties, OT is used as a treatment for labor induction, postpartum hemorrhage, and lactation support. The potential use of OT in the treatment of central nervous system (CNS)-related diseases has recently renewed interest in the pharmacology of OT. Oxytocin is one of the most extensively studied cyclic peptides and since the elucidation of its structure in 1953 thousands of peptidic OT analogs with antagonistic and agonistic properties have been synthesized and biologically evaluated. Among them are atosiban, a mixed oxytocin receptor (OTR)/vasopressin 1a receptor (V1aR) antagonist used as a tocolytic agent approved (in certain countries), and carbetocin, a longer acting OTR agonist on the market for the treatment of postpartum hemorrhage. Many other OT analogs with improved pharmacological properties (e.g., barusiban, Antag III) have been identified. These peptides have been tested in clinical trials and/or used as pharmacological tools. In this chapter, the modifications of the OT molecule that led to the discovery of these compounds are reviewed.
Collapse
|
4
|
Muttenthaler M, Andersson Å, Vetter I, Menon R, Busnelli M, Ragnarsson L, Bergmayr C, Arrowsmith S, Deuis JR, Chiu HS, Palpant NJ, O'Brien M, Smith TJ, Wray S, Neumann ID, Gruber CW, Lewis RJ, Alewood PF. Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species. Sci Signal 2017; 10:10/508/eaan3398. [PMID: 29208680 DOI: 10.1126/scisignal.aan3398] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Oxytocin and vasopressin mediate various physiological functions that are important for osmoregulation, reproduction, cardiovascular function, social behavior, memory, and learning through four G protein-coupled receptors that are also implicated in high-profile disorders. Targeting these receptors is challenging because of the difficulty in obtaining ligands that retain selectivity across rodents and humans for translational studies. We identified a selective and more stable oxytocin receptor (OTR) agonist by subtly modifying the pharmacophore framework of human oxytocin and vasopressin. [Se-Se]-oxytocin-OH displayed similar potency to oxytocin but improved selectivity for OTR, an effect that was retained in mice. Centrally infused [Se-Se]-oxytocin-OH potently reversed social fear in mice, confirming that this action was mediated by OTR and not by V1a or V1b vasopressin receptors. In addition, [Se-Se]-oxytocin-OH produced a more regular contraction pattern than did oxytocin in a preclinical labor induction and augmentation model using myometrial strips from cesarean sections. [Se-Se]-oxytocin-OH had no activity in human cardiomyocytes, indicating a potentially improved safety profile and therapeutic window compared to those of clinically used oxytocin. In conclusion, [Se-Se]-oxytocin-OH is a novel probe for validating OTR as a therapeutic target in various biological systems and is a promising new lead for therapeutic development. Our medicinal chemistry approach may also be applicable to other peptidergic signaling systems with similar selectivity issues.
Collapse
Affiliation(s)
- Markus Muttenthaler
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. .,Faculty of Chemistry, Institute of Biological Chemistry, University of Vienna, 1090 Vienna, Austria
| | - Åsa Andersson
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Irina Vetter
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.,School of Pharmacy, The University of Queensland, Brisbane, Queensland 4104, Australia
| | - Rohit Menon
- Department of Behavioral and Molecular Neurobiology, Regensburg Center of Neuroscience, University of Regensburg, 93053 Regensburg, Germany
| | - Marta Busnelli
- CNR-Institute of Neuroscience, 20129 Milan, Italy.,Department of Biotechnology and Translational Medicine, University of Milan, 20129 Milan, Italy
| | - Lotten Ragnarsson
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Christian Bergmayr
- Center for Physiology and Pharmacology, Medical University of Vienna, 1090 Vienna, Austria
| | - Sarah Arrowsmith
- Department of Cellular and Molecular Physiology, Harris-Wellbeing Preterm Birth Centre, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3BX, UK
| | - Jennifer R Deuis
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Han Sheng Chiu
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Nathan J Palpant
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Margaret O'Brien
- National Centre for Biomedical Engineering Science, National University of Ireland, Galway H91 CF50, Ireland
| | - Terry J Smith
- National Centre for Biomedical Engineering Science, National University of Ireland, Galway H91 CF50, Ireland
| | - Susan Wray
- Department of Cellular and Molecular Physiology, Harris-Wellbeing Preterm Birth Centre, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3BX, UK
| | - Inga D Neumann
- Department of Behavioral and Molecular Neurobiology, Regensburg Center of Neuroscience, University of Regensburg, 93053 Regensburg, Germany
| | - Christian W Gruber
- Center for Physiology and Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.,School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Richard J Lewis
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Paul F Alewood
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.
| |
Collapse
|
5
|
Geng CH, Wang C, Yang J, Wang H, Ma RQ, Liu X, Wang CH. Arginine vasopressin improves the memory deficits in Han Chinese patients with first-episode schizophrenia. Peptides 2017; 97:8-15. [PMID: 28882471 DOI: 10.1016/j.peptides.2017.09.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2016] [Revised: 08/29/2017] [Accepted: 09/02/2017] [Indexed: 11/18/2022]
Abstract
The memory impairment is a core deficit in the first-episode schizophrenia patients. Arginine vasopressin (AVP) in the brain can improve learning and memory. We performed multicentre, randomized, double-blind, placebo-controlled, parallel-group clinical trial to study the cognitive functioning in Han Chinese first-episode schizophrenic patients in a 12-week treatment regime with the intranasal administration of AVP (128 cases) or placebo (131 cases) in addition to the conventional treatment. The methods of positive and negative syndrome scale (PANSS), Wechsler memory scale-4th edition (WMS-IV) and event-related potential (ERP) were used to study the effects of AVP on the cognitive function. The results showed that (1) AVP concentration decreased in cerebrospinal fluid (CSF) of the right-handed Han Chinese first-episode schizophrenic patients comparing with that of the health volunteers (7.1±1.5pg/ml vs 13.3±1.9pg/ml, p<0.01), and did not change in plasma; (2) AVP significantly improved PANSS scores including total scores, positive symptoms, negative symptoms and general psychopathology comparing with those of the placebo group; (3) AVP elevated WMS-IV scores including the long-term memory (accumulation), short-term memory (recognition, comprehension), immediate memory (number recitation) and memory quotient 4, 8 and 12 weeks after treatment; and (4) AVP did not influence the latency and wave amplitude of target stimulus of P300 of right-handed Han Chinese first-episode schizophrenic patients. The data suggested that AVP might improve cognitive process, such as memorizing and extraction of the information although there were many changes of cognitive functions in the right-handed Han Chinese first-episode schizophrenic patients.
Collapse
Affiliation(s)
- Cai-Hong Geng
- The Second Affiliated Hospital of Xinxiang Medical University and Henan Province Mental Hospital, Xinxiang, Henan 453002, China
| | - Chao Wang
- The Second Affiliated Hospital of Xinxiang Medical University and Henan Province Mental Hospital, Xinxiang, Henan 453002, China
| | - Jun Yang
- Xinxiang Institute for New Medicine, Xinxing, Henan 453003, China; Xinjiang Hongda Food & Beverage Ltd., Xinjiang, Shanxi 043110, China.
| | - Hua Wang
- Xinxiang Institute for New Medicine, Xinxing, Henan 453003, China; Xinjiang Hongda Food & Beverage Ltd., Xinjiang, Shanxi 043110, China
| | - Rui-Qing Ma
- Xinxiang Institute for New Medicine, Xinxing, Henan 453003, China
| | - Xu Liu
- The Second Affiliated Hospital of Xinxiang Medical University and Henan Province Mental Hospital, Xinxiang, Henan 453002, China
| | - Chang-Hong Wang
- The Second Affiliated Hospital of Xinxiang Medical University and Henan Province Mental Hospital, Xinxiang, Henan 453002, China
| |
Collapse
|
6
|
DeAngelis R, Gogola J, Dodd L, Rhodes JS. Opposite effects of nonapeptide antagonists on paternal behavior in the teleost fish Amphiprion ocellaris. Horm Behav 2017; 90:113-119. [PMID: 28288796 DOI: 10.1016/j.yhbeh.2017.02.013] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/27/2016] [Revised: 02/15/2017] [Accepted: 02/23/2017] [Indexed: 01/18/2023]
Abstract
The nonapeptides isotocin (IT) and arginine vasotocin (AVT), along with their mammalian homologs oxytocin and arginine vasopressin, are well known regulators of social behaviors across vertebrate taxa. However, little is known about their involvement in paternal care. Here, we measured the effect of an IT and an AVT V1a receptor antagonist on paternal behaviors in the primarily paternal teleost Amphiprion ocellaris. We also measured the effect of the IT receptor antagonist on aggression in dyadic contests between two non-reproductive fish to assess specificity of the effect on paternal behaviors. Individual differences in levels of paternal behaviors (nips, fanning the eggs, and proportion of the time in the nest) were consistent across spawning cycles when no treatments were administered. The IT receptor antagonist severely reduced paternal behaviors but had no effect on aggression, whereas the AVT V1a receptor antagonist increased paternal behaviors. These results support the idea that IT signaling is crucial for the expression of paternal behavior in A. ocellaris. Based on a previous study showing that the AVT V1a antagonist decreases aggression in dyadic contests, we hypothesize that the antagonist enhances paternal behavior indirectly by reducing vigilance and aggression, thereby alleviating effort directed towards other competing behaviors and allowing for the increased expression of paternal behaviors.
Collapse
Affiliation(s)
- Ross DeAngelis
- Program for Ecology, Evolution and Conservation Biology, University of Illinois at Urbana, Champaign, 405 N. Mathews Ave, Urbana, IL 61801, USA; Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana, Champaign, 405 N. Mathews Ave, Urbana, IL 61801, USA.
| | - Joseph Gogola
- Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana, Champaign, 405 N. Mathews Ave, Urbana, IL 61801, USA
| | - Logan Dodd
- Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana, Champaign, 405 N. Mathews Ave, Urbana, IL 61801, USA
| | - Justin S Rhodes
- Program for Ecology, Evolution and Conservation Biology, University of Illinois at Urbana, Champaign, 405 N. Mathews Ave, Urbana, IL 61801, USA; Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana, Champaign, 405 N. Mathews Ave, Urbana, IL 61801, USA
| |
Collapse
|
7
|
Passoni I, Leonzino M, Gigliucci V, Chini B, Busnelli M. Carbetocin is a Functional Selective Gq Agonist That Does Not Promote Oxytocin Receptor Recycling After Inducing β-Arrestin-Independent Internalisation. J Neuroendocrinol 2016; 28. [PMID: 26751410 PMCID: PMC5021139 DOI: 10.1111/jne.12363] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2015] [Revised: 12/30/2015] [Accepted: 01/07/2016] [Indexed: 01/08/2023]
Abstract
Carbetocin, a long-acting oxytocin analogue, has been reported to elicit interesting and peculiar behavioural effects. The present study investigated the molecular pharmacology of carbetocin, aiming to better understand the molecular basis of its action in the brain. Using bioluminescence resonance energy transfer biosensors, we characterised the effects of carbetocin on the three human oxytocin/vasopressin receptors expressed in the nervous system: the oxytocin receptor (OXTR) and the vasopressin V1a (V1aR) and V1b (V1bR) receptors. Our results indicate that (i) carbetocin activates the OXTR but not the V1aR and V1bR at which it may act as an antagonist; (ii) carbetocin selectively activates only the OXTR/Gq pathway displaying a strong functional selectivity; (iii) carbetocin is a partial agonist at the OXTR/Gq coupling; (iv) carbetocin promotes OXTR internalisation via a previously unreported β-arrestin-independent pathway; and (v) carbetocin does not induce OXTR recycling to the plasma membrane. Altogether, these molecular pharmacology features identify carbetocin as a substantially different analogue compared to the endogenous oxytocin and, consequently, carbetocin is not expected to mimic oxytocin in the brain. Whether these unique features of carbetocin could be exploited therapeutically remains to be established.
Collapse
Affiliation(s)
- I Passoni
- Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy
| | - M Leonzino
- CNR, Institute of Neuroscience, Milan, Italy
| | - V Gigliucci
- CNR, Institute of Neuroscience, Milan, Italy
| | - B Chini
- CNR, Institute of Neuroscience, Milan, Italy
- Humanitas Clinical and Research Institute, Rozzano, Italy
| | - M Busnelli
- Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy
- CNR, Institute of Neuroscience, Milan, Italy
| |
Collapse
|
8
|
Koga K, Yoshinaga M, Uematsu Y, Nagai Y, Miyakoshi N, Shimoda Y, Fujinaga M, Minamimoto T, Zhang MR, Higuchi M, Ohtake N, Suhara T, Chaki S. TASP0434299: A Novel Pyridopyrimidin-4-One Derivative as a Radioligand for Vasopressin V1B Receptor. J Pharmacol Exp Ther 2016; 357:495-508. [PMID: 27029585 DOI: 10.1124/jpet.116.232942] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Accepted: 03/28/2016] [Indexed: 12/11/2022] Open
Abstract
A novel pyridopyrimidin-4-one derivative, N-tert-butyl-2-[2-(3-methoxyphenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl]acetamide (TASP0434299), was characterized as a radioligand candidate for arginine vasopressin 1B (V1B) receptor. TASP0434299 exhibited high binding affinities for human and rat V1B receptors with IC50 values of 0.526 and 0.641 nM, respectively, and potent antagonistic activity at the human V1B receptor with an IC50 value of 0.639 nM without apparent binding affinities for other molecules at 1 μM. [(3)H]TASP0434299 bound to membranes expressing the human V1B receptor as well as those prepared from the rat anterior pituitary in a saturable manner. The binding of [(3)H]TASP0434299 to the membranes was dose-dependently displaced by several ligands for the V1B receptor. In addition, the intravenous administration of [(3)H]TASP0434299 to rats produced a saturable radioactive accumulation in the anterior pituitary where the V1B receptor is enriched, and it was dose-dependently blocked by the oral administration of 2-[2-(3-chloro-4-fluorophenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl]-N-isopropylacetamide hydrochloride, a V1B receptor antagonist, indicating that [(3)H]TASP0434299 can be used as an in vivo radiotracer to measure the occupancy of the V1B receptor. Finally, the intravenous administration of [(11)C]TASP0434299 provided positron emission tomographic images of the V1B receptor in the pituitary in an anesthetized monkey, and the signal was blocked by pretreatment with an excess of unlabeled TASP0434299. These results indicate that radiolabeled TASP0434299 is the first radioligand to be capable of quantifying the V1B receptor selectively in both in vitro and in vivo studies and will provide a clinical biomarker for determining the occupancy of the V1B receptor during drug development or for monitoring the levels of the V1B receptor in diseased conditions.
Collapse
Affiliation(s)
- Kazumi Koga
- Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
| | - Mitsukane Yoshinaga
- Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
| | - Yoshikatsu Uematsu
- Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
| | - Yuji Nagai
- Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
| | - Naoki Miyakoshi
- Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
| | - Yoko Shimoda
- Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
| | - Masayuki Fujinaga
- Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
| | - Takafumi Minamimoto
- Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
| | - Ming-Rong Zhang
- Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
| | - Makoto Higuchi
- Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
| | - Norikazu Ohtake
- Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
| | - Tetsuya Suhara
- Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
| | - Shigeyuki Chaki
- Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
| |
Collapse
|
9
|
Marir R, Virsolvy A, Wisniewski K, Mion J, Haddou D, Galibert E, Meraihi Z, Desarménien MG, Guillon G. Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist. Br J Pharmacol 2014; 170:278-92. [PMID: 23725319 DOI: 10.1111/bph.12249] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2012] [Revised: 05/03/2013] [Accepted: 05/20/2013] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND AND PURPOSE Distinct vasopressin receptors are involved in different physiological and behavioural functions. Presently, no selective agonist is available to specifically elucidate the functional roles of the V1A receptor in the rat, one of the most widely used animal models. FE 201874 is a new derivative of the human selective V1A receptor agonist F180. In this study, we performed a multi-approach pharmacological and functional characterization of FE 201874 to determine whether it is selective for V1A receptors. EXPERIMENTAL APPROACH We modified an available human selective V1A receptor agonist (F180) and determined its pharmacological properties in cell lines expressing vasopressin/oxytocin receptors (affinity and coupling to second messenger cascades), in an ex vivo model (aorta ring contraction) and in vivo in rats (proliferation of adrenal cortex glomerulosa cells and lactation). KEY RESULTS FE 201874 exhibited nanomolar affinity for the rat V1A receptor; it was highly selective towards the rat V1B and V2 vasopressin receptors and behaved as a full V1A agonist in all the pharmacological tests performed. FE 201874 bound to the oxytocin receptor, but with moderate affinity, and behaved as an oxytocin antagonist in vitro, but not in vivo. CONCLUSIONS AND IMPLICATIONS On functional grounds, all the data demonstrate that FE 201874 is the first selective agonist of the rat V1A receptor isoform available. Hence, FE 201874 may have potential as a treatment for the vasodilator-induced hypotension occurring in conditions such as septic shock and could be the most suitable compound for discriminating between the behavioural effects of arginine vasopressin and oxytocin.
Collapse
Affiliation(s)
- Rafik Marir
- CNRS, UMR-5203, Institut de Génomique Fonctionnelle, Montpellier, F-34094, France; INSERM, U661, Montpellier, F-34094, France; Universités de Montpellier 1 & 2, UMR-5203, Montpellier, F-34094, France; Université Constantine 1, Faculté des sciences de la nature et de la vie, Constantine, Algérie
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Blockade of arginine vasotocin signaling reduces aggressive behavior and c-Fos expression in the preoptic area and periventricular nucleus of the posterior tuberculum in male Amphiprion ocellaris. Neuroscience 2014; 267:205-18. [DOI: 10.1016/j.neuroscience.2014.02.045] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2013] [Revised: 02/22/2014] [Accepted: 02/28/2014] [Indexed: 12/28/2022]
|
11
|
Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b Receptors: From Molecules to Physiological Systems. Physiol Rev 2012; 92:1813-64. [DOI: 10.1152/physrev.00035.2011] [Citation(s) in RCA: 250] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The neurohypophysial hormone arginine vasopressin (AVP) is essential for a wide range of physiological functions, including water reabsorption, cardiovascular homeostasis, hormone secretion, and social behavior. These and other actions of AVP are mediated by at least three distinct receptor subtypes: V1a, V1b, and V2. Although the antidiuretic action of AVP and V2 receptor in renal distal tubules and collecting ducts is relatively well understood, recent years have seen an increasing understanding of the physiological roles of V1a and V1b receptors. The V1a receptor is originally found in the vascular smooth muscle and the V1b receptor in the anterior pituitary. Deletion of V1a or V1b receptor genes in mice revealed that the contributions of these receptors extend far beyond cardiovascular or hormone-secreting functions. Together with extensively developed pharmacological tools, genetically altered rodent models have advanced the understanding of a variety of AVP systems. Our report reviews the findings in this important field by covering a wide range of research, from the molecular physiology of V1a and V1b receptors to studies on whole animals, including gene knockout/knockdown studies.
Collapse
Affiliation(s)
- Taka-aki Koshimizu
- Department of Pharmacology, Division of Molecular Pharmacology, Jichi Medical University, Tochigi, Japan; Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan; and Department of Internal Medicine, Kitasato University, Kitasato Institute Medical Center Hospital, Saitama, Japan
| | - Kazuaki Nakamura
- Department of Pharmacology, Division of Molecular Pharmacology, Jichi Medical University, Tochigi, Japan; Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan; and Department of Internal Medicine, Kitasato University, Kitasato Institute Medical Center Hospital, Saitama, Japan
| | - Nobuaki Egashira
- Department of Pharmacology, Division of Molecular Pharmacology, Jichi Medical University, Tochigi, Japan; Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan; and Department of Internal Medicine, Kitasato University, Kitasato Institute Medical Center Hospital, Saitama, Japan
| | - Masami Hiroyama
- Department of Pharmacology, Division of Molecular Pharmacology, Jichi Medical University, Tochigi, Japan; Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan; and Department of Internal Medicine, Kitasato University, Kitasato Institute Medical Center Hospital, Saitama, Japan
| | - Hiroshi Nonoguchi
- Department of Pharmacology, Division of Molecular Pharmacology, Jichi Medical University, Tochigi, Japan; Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan; and Department of Internal Medicine, Kitasato University, Kitasato Institute Medical Center Hospital, Saitama, Japan
| | - Akito Tanoue
- Department of Pharmacology, Division of Molecular Pharmacology, Jichi Medical University, Tochigi, Japan; Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan; and Department of Internal Medicine, Kitasato University, Kitasato Institute Medical Center Hospital, Saitama, Japan
| |
Collapse
|
12
|
Yang J, Pan YJ, Yin ZK, Hai GF, Lu L, Zhao Y, Wang DX, Wang H, Wang G. Effect of arginine vasopressin on the behavioral activity in the behavior despair depression rat model. Neuropeptides 2012; 46:141-9. [PMID: 22513399 DOI: 10.1016/j.npep.2012.03.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2012] [Revised: 03/24/2012] [Accepted: 03/26/2012] [Indexed: 02/03/2023]
Abstract
Arginine vasopressin (AVP), a nonapeptide posterior hormone of the pituitary, is mainly synthesized and secreted in the hypothalamic paraventricular nucleus (PVN) and supraoptic nucleus (SON). Large numbers of studies have reported that AVP plays a role in depression. The present study was to investigate by which level, brain or periphery, AVP affects the behavioral activity in the behavior despair depression rat model. The results showed that (1) either forced swimming or tail suspension significantly increased AVP concentration not only in the brain (PVN, SON, frontal of cortex, hippocampus, amygdala, lumber spinal cord) but also in the periphery (posterior pituitary and serum); (2) intraventricular injection (icv) of AVP decreased the animal immobility time, whereas V₁ receptor antagonist d(CH₂)₅Tyr(Me)AVP (icv) increased the animal immobility time in a dose-dependent manner not only in FST but also in TST, but the V₂ receptor antagonist d(CH₂)₅[D-Ile, Ile, Ala-NH₉]AVP did not change the animal immobility time in FST or TST; (3) V₁, not V₂ receptor antagonist could inhibit the animal immobility time decrease induced by AVP (icv); (4) neither AVP nor its receptor antagonist (including V₁ and V₂ receptor antagonist) influenced the animal immobility time in both FST and TST. The data suggested that AVP in the brain rather than the periphery played a role in the behavior despair depression by V₁, not V₂ receptors, which behavior despair might have a positive feedback effect on central AVP and blood AVP might have a negative feedback on central AVP in the depressive process.
Collapse
Affiliation(s)
- Jun Yang
- College of Pharmacy, Xinxiang Medical University, Xinxiang, Henan 453003, China.
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Suzuki H, Kawasaki M, Ohnishi H, Nakamura T, Ueta Y. Regulatory mechanism of the arginine vasopressin-enhanced green fluorescent protein fusion gene expression in acute and chronic stress. Peptides 2009; 30:1763-70. [PMID: 19505519 DOI: 10.1016/j.peptides.2009.05.025] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2009] [Revised: 05/26/2009] [Accepted: 05/27/2009] [Indexed: 11/17/2022]
Abstract
Various kinds of stress cause neuroendocrine responses such as corticotropin-releasing hormone (CRH) or arginine vasopressin (AVP) release from parvocellular division of the paraventricular nucleus (PVN) and activation of the hypothalamo-pituitary adrenal (HPA) axis. We examined the effects of acute and chronic stress on the expression of the AVP-enhanced green fluorescent protein (eGFP) fusion gene in the hypothalamus, using chronic salt loading as an osmotic stimulation, intraperitoneal administration of lipopolysaccharide (LPS) as acute inflammatory stress and adjuvant arthritis (AA) as chronic inflammatory/nociceptive stress. Salt loading caused a marked increase in the eGFP gene expression and eGFP fluorescence in the supraoptic nucleus, magnocellular division of the PVN and internal layer of the median eminence (ME). Administration of LPS caused increased fluorescence in parvocellular division of the PVN and external layer of the ME. AA rats revealed an increased expression of the eGFP gene and eGFP fluorescence in both magnocellular and parvocellular divisions of the PVN and both internal and external layers of the ME. On the other hand, the levels of the CRH gene expression in parvocellular division of the PVN were significantly decreased as AA developed, though plasma concentrations of corticosterone were significantly increased. These results indicate that AVP-eGFP transgenic rats enable the detection of changes in AVP expression more easily than by using procedures such as immunohistochemistry. We propose that AVP-eGFP transgenic rats represent a useful animal model for further understanding of the physiology of AVP expression in the hypothalamo-pituitary system under various physiological conditions, including various kinds of stress.
Collapse
Affiliation(s)
- Hitoshi Suzuki
- Department of Physiology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| | | | | | | | | |
Collapse
|
14
|
Zhou Y, Leri F, Cummins E, Hoeschele M, Kreek MJ. Involvement of arginine vasopressin and V1b receptor in heroin withdrawal and heroin seeking precipitated by stress and by heroin. Neuropsychopharmacology 2008; 33:226-36. [PMID: 17443128 DOI: 10.1038/sj.npp.1301419] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
A previous study has shown that the stress responsive neurohormone arginine vasopressin (AVP) is activated in the amygdala during early withdrawal from cocaine. The present studies were undertaken to determine whether (1) AVP mRNA levels in the amygdala or hypothalamus, as well as hypothalamic-pituitary-adrenal (HPA) activity, would be altered during chronic intermittent escalating heroin administration (10 days; 7.5-60 mg/kg/day) or during early (12 h) and late (10 days) spontaneous withdrawal; (2) foot shock stress would alter AVP mRNA levels in the amygdala or hypothalamus in rats withdrawn from heroin self-administration (7 days, 3 h/day, 0.05 mg/kg/infusion); and (3) the selective V1b receptor antagonist SSR149415 (1 and 30 mg/kg, intraperitoneal) would alter heroin seeking during tests of reinstatement induced by foot shock stress and by heroin primes (0.25 mg/kg), as well as HPA hormonal responses to foot shock. We found that AVP mRNA levels were increased during early spontaneous withdrawal in the amygdala only. This amygdalar AVP mRNA increase was no longer observed at the later stage of heroin withdrawal. Foot shock stress increased AVP mRNA levels in the amygdala of rats withdrawn from heroin self-administration, but not in heroin naïve rats. Behaviorally, SSR149415 dose-dependently attenuated foot shock-induced reinstatement and blocked heroin-induced reinstatement. Finally, SSR149415 blunted the HPA activation by foot shock. Together, these data in rats suggest that stress responsive AVP/V1b receptor systems (including the amygdala) may be critical components of the neural circuitry underlying the aversive emotional consequences of drug withdrawal, as well as the effect of negative emotional states on drug-seeking behavior.
Collapse
Affiliation(s)
- Yan Zhou
- Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY 10021, USA.
| | | | | | | | | |
Collapse
|
15
|
Allaman-Exertier G, Reymond-Marron I, Tribollet E, Raggenbass M. Vasopressin modulates lateral septal network activity via two distinct electrophysiological mechanisms. Eur J Neurosci 2007; 26:2633-42. [DOI: 10.1111/j.1460-9568.2007.05866.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Pena A, Murat B, Trueba M, Ventura MA, Bertrand G, Cheng LL, Stoev S, Szeto HH, Wo N, Brossard G, Serradeil-Le Gal C, Manning M, Guillon G. Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors. Endocrinology 2007; 148:4136-46. [PMID: 17495006 DOI: 10.1210/en.2006-1633] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Recently, we synthesized and characterized the first selective V(1b) vasopressin (VP)/oxytocin receptor agonist, d[Cha(4)]arginine vasopressin. However, this agonist was only selective for the human receptors. We thus decided to design a selective V(1b) agonist for the rodent species. We started from previous observations showing that modifying [deamino(1),Arg(8)]VP in positions 4 and 8 altered the rat VP/oxytocin receptor selectivity. We synthesized a series of 13 [deamino(1),Arg(8)]VP analogs modified in positions 4 and 8. Among them, one seemed very promising, d[Leu(4), Lys(8)]VP. In this paper, we describe its pharmacological and physiological properties. This analog exhibited a nanomolar affinity for the rat, human, and mouse V(1b) VP receptors and a strong V(1b) selectivity for the rat species. On AtT20 cells stably transfected with the rat V(1b) receptor, d[Leu(4), Lys(8)]VP behaved as a full agonist on both phospholipase C and MAPK assays. Additional experiments revealed its ability to induce the internalization of enhanced green fluorescent protein-tagged human and mouse V(1b) receptors as expected for a full agonist. Additional physiological experiments were performed to further confirm the selectivity of this peptide. Its antidiuretic, vasopressor, and in vitro oxytocic activities were weak compared with those of VP. In contrast, used at low doses, its efficiency to stimulate adrenocorticotropin or insulin release from mouse pituitary or perfused rat pancreas, respectively, was similar to that obtained with VP. In conclusion, d[Leu(4), Lys(8)]VP is the first selective agonist available for the rat V(1b) VP receptor. It will allow a better understanding of V(1b) receptor-mediated effects in rodents.
Collapse
Affiliation(s)
- Ana Pena
- Institut de Génomique Fonctionnelle, Département d'Endocrinologie, 141 rue de la Cardonille, 34094 Montpellier Cedex 05, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Serradeil-Le Gal C, Raufaste D, Derick S, Blankenstein J, Allen J, Pouzet B, Pascal M, Wagnon J, Ventura MA. Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand. Am J Physiol Regul Integr Comp Physiol 2007; 293:R938-49. [PMID: 17522130 DOI: 10.1152/ajpregu.00062.2007] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
[3H]SSR-149415 is the first tritiated nonpeptide vasopressin V1b receptor (V1bR) antagonist ligand. It was used for studying rodent (mouse, rat, hamster) and human V1bR from native or recombinant origin. Moreover, a close comparison between the human and the mouse V1bR was performed using SSR-149415/[3H]SSR-149415 in binding and functional studies in vitro. [3H]SSR-149415 binding was time-dependent, reversible, and saturable. Scatchard plot analysis gave a single class of high-affinity binding sites with apparent equilibrium dissociation constant ( Kd) ∼1 nM and maximum binding density (Bmax) values from 7,000 to 300,000 sites/cell according to the cell line. In competition experiments, [3H]SSR-149415 binding was stereospecific and dose-dependently displaced by reference peptide and nonpeptide arginine vasopressin (AVP)/OT ligands following a V1b rank order of affinity: SSR-149415 = AVP > dCha > dPen > dPal > dDavp > SSR-126768A > SR-49059 > SSR-149424 > OT > SR-121463B. Species differences between human, rat, mouse, and hamster V1bR were observed. Autoradiography studies with [3H]SSR-149415 on rat and human pituitary showed intense specific labeling confined to corticotroph cells and absence of labeling in the other tissues examined. SSR-149415 potently and stereospecifically antagonized the AVP-induced inositol phosphate production and intracellular Ca2+ increase (EC50 from 1.83 to 3.05 nM) in recombinant cell lines expressing either the mouse or the human V1bR. AVP (10−7 M) exposure of AtT20 cells expressing mouse or human EGFP-tagged V1bR induced their rapid internalization. Preincubation with 10−6 M SSR-149415 counteracted the internalization process. Moreover, recycling of internalized receptors was observed upon 10−6 M SSR-149415 treatment. Thus SSR-149415/[3H]SSR-149415 are unique tools for studying animal and human V1bR.
Collapse
Affiliation(s)
- Claudine Serradeil-Le Gal
- Sanofi-Aventis Recherche and Développement, Exploratory Research Department, 195, route d'Espagne, BP 1169, 31036 Toulouse Cedex, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Blakeney JS, Reid RC, Le GT, Fairlie DP. Nonpeptidic Ligands for Peptide-Activated G Protein-Coupled Receptors. Chem Rev 2007; 107:2960-3041. [PMID: 17622179 DOI: 10.1021/cr050984g] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jade S Blakeney
- Centre for Drug Design and Development, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | | | | | | |
Collapse
|
19
|
Reymond-Marron I, Tribollet E, Raggenbass M. The vasopressin-induced excitation of hypoglossal and facial motoneurons in young rats is mediated by V1a but not V1b receptors, and is independent of intracellular calcium signalling. Eur J Neurosci 2006; 24:1565-74. [PMID: 17004920 DOI: 10.1111/j.1460-9568.2006.05038.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
As a hormone, vasopressin binds to three distinct receptors: V1a and V1b receptors, which induce phospholipase-Cbeta (PLCbeta) activation and Ca2+ mobilization; and V2 receptors, which are coupled to adenylyl cyclase. V1a and V1b receptors are also present in neurons. In particular, hypoglossal (XII) and facial (VII) motoneurons are excited following vasopressin-V1a receptor binding. The aim of the present study was double: (i) to determine whether V1b receptors contribute to the excitatory effect of vasopressin in XII and VII motoneurons; and (ii) to establish whether the action of vasopressin on motoneurons is mediated by Ca2+ signalling. Patch-clamp recordings were performed in brainstem slices of young rats. Vasopressin depolarized the membrane or generated an inward current. By contrast, [1-deamino-4-cyclohexylalanine] arginine vasopressin (d[Cha4]AVP), a V1b agonist, had no effect. The action of vasopressin was suppressed by Phaa-D-Tyr(Et)-Phe-Gln-Asn-Lys-Pro-Arg-NH2, a V1a antagonist, but not by SSR149415, a V1b antagonist. Thus, the vasopressin-induced excitation of brainstem motoneurons was exclusively mediated by V1a receptors. Light microscopic autoradiography failed to detect V1b binding sites in the facial nucleus. In motoneurons loaded with GTP-gamma-S, a non-hydrolysable analogue of GTP, the effect of vasopressin was suppressed, indicating that neuronal V1a receptors are G-protein-coupled. Intracellular Ca2+ chelation suppressed a Ca2+-activated potassium current, but did not affect the vasopressin-evoked current. H7 and GF109203, inhibitors of protein kinase C, were without effect on the vasopressin-induced excitation. U73122 and D609, PLCbeta inhibitors, were also without effect. Thus, excitation of brainstem motoneurons by V1a receptor activation is probably mediated by a second messenger distinct from that associated with peripheral V1a receptors.
Collapse
Affiliation(s)
- I Reymond-Marron
- Department of Basic Neurosciences, University Medical Center, CH-1211 Geneva 4, Switzerland
| | | | | |
Collapse
|
20
|
Milutinović S, Murphy D, Japundzić-Zigon N. The role of central vasopressin receptors in the modulation of autonomic cardiovascular controls: a spectral analysis study. Am J Physiol Regul Integr Comp Physiol 2006; 291:R1579-91. [PMID: 17085750 DOI: 10.1152/ajpregu.00764.2005] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Although it has been suggested that vasopressin (VP) acts within the central nervous system to modulate autonomic cardiovascular controls, the mechanisms involved are not understood. Using nonpeptide, selective V(1a), V(1b), and V(2) antagonists, in conscious rats, we assessed the roles of central VP receptors, under basal conditions, after the central application of exogenous VP, and after immobilization, on cardiovascular short-term variability. Equidistant sampling of blood pressure (BP) and heart rate (HR) at 20 Hz allowed direct spectral analysis in very-low frequency (VLF-BP), low-frequency (LF-BP), and high-frequency (HF-BP) blood pressure domains. The effect of VP antagonists and of exogenous VP on body temperature (T(b)) was also investigated. Under basal conditions, V(1a) antagonist increased HF-BP and T(b), and this was prevented by metamizol. V(1b) antagonist enhanced HF-BP without affecting T(b), and V(2) antagonist increased VLF-BP variability which could be prevented by quinapril. Immobilization increased BP, LF-BP, HF-BP, and HF-HR variability. V(1a) antagonist prevented BP and HR variability changes induced by immobilization and potentiated tachycardia. V(1b) antagonist prevented BP but not HR variability changes, whereas V(2) antagonist had no effect. Exogenous VP increased systolic arterial pressure (SAP) and HF-SAP variability, and this was prevented by V(1a) and V(1b) but not V(2) antagonist pretreatment. Our results suggest that, under basal conditions, VP, by stimulation of V(1a), V(1b), and cognate V(2) receptors, buffers BP variability, mostly due to thermoregulation. Immobilization and exogenous VP, by stimulation of V(1a) or V(1b), but not V(2) receptors, increases BP variability, revealing cardiorespiratory adjustment to stress and respiratory stimulation, respectively.
Collapse
Affiliation(s)
- Sanja Milutinović
- Laboratory for Cardiovascular Pharmacology, Institute of Pharmacology, Clinical Pharmacology and Toxicology, 11129 Belgrade, Serbia
| | | | | |
Collapse
|
21
|
Müller MB, Holsboer F. Mice with mutations in the HPA-system as models for symptoms of depression. Biol Psychiatry 2006; 59:1104-15. [PMID: 16581037 DOI: 10.1016/j.biopsych.2006.02.008] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2005] [Revised: 01/20/2006] [Accepted: 02/15/2006] [Indexed: 12/19/2022]
Abstract
Genetically engineered mice hold promise to help us understand the effects of enhanced or reduced gene activity upon behavior and metabolism. Because many basic and clinical studies suggest that alterations of the hypothalamic pituitary adrenocortical (HPA) system are involved in the development and course of depression, mouse mutants with genetic modifications of genes regulating the HPA system were generated. This review summarizes these effects and concludes that advanced technologies allowing for regional overexpression or inactivation of genes or introduction of polymorphisms into the mouse genome are well suited to explain individual symptoms or symptom patterns prevalent among depressives. However, as depression is a complex disorder in which minor changes of many genes as well as environmental factors (including epigenetic programming) play a causal role and determine the phenotype, the use of mice with single gene mutations needs to be critically discussed when attempting to create a genetic animal model of depression.
Collapse
Affiliation(s)
- Marianne B Müller
- Max Planck Institute of Psychiatry, Kraepelinstr. 2-10, 80804 Munich, Germany
| | | |
Collapse
|
22
|
Goldstein DL. Regulation of the avian kidney by arginine vasotocin. Gen Comp Endocrinol 2006; 147:78-84. [PMID: 16288753 DOI: 10.1016/j.ygcen.2005.09.018] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2005] [Revised: 09/07/2005] [Accepted: 09/21/2005] [Indexed: 11/19/2022]
Abstract
Nonapeptides secreted by the neurohypophysis have important roles in vertebrate cardio-fluid homeostasis. In birds, those peptides include mesotocin (the representative of the neutral, or oxytocin-like, nonapeptide family) and vasotocin (the representative of the basic, or vasopressin-like, hormones). The function of mesotocin is not well defined, but it does appear to have osmoregulatory functions. Vasotocin is considered the primary avian antidiuretic hormone. Receptors for AVT in avian kidney-either on renal vasculature or on the tubules-have yet to be localized or identified. However, AVT quite certainly effects antidiuresis via both vascular and tubular mechanisms. The former entail a reduction in the rate of glomerular filtration, apparently via constriction of afferent arterioles. Evidence for the latter (direct tubular action of AVT) has accumulated in recent years and includes enhanced fractional tubular water reabsorption, activation of second messenger (cAMP) in thick ascending limbs and collecting ducts, and modest AVT-stimulated water permeability in collecting ducts associated with expression of aquaporins. The relative importance of the renal vascular vs. tubular actions in birds likely depend on the dose of the hormone, the physiological condition of the animal, and the species of bird.
Collapse
Affiliation(s)
- David L Goldstein
- Department of Biological Sciences, Wright State University, Dayton, OH 45435, USA.
| |
Collapse
|
23
|
Vedernikov YP, Betancourt A, Wentz MJ, Saade GR, Garfield RE. Adaptation to pregnancy leads to attenuated rat uterine artery smooth muscle sensitivity to oxytocin. Am J Obstet Gynecol 2006; 194:252-60. [PMID: 16389040 DOI: 10.1016/j.ajog.2005.05.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2004] [Revised: 03/29/2005] [Accepted: 05/02/2005] [Indexed: 10/25/2022]
Abstract
OBJECTIVE We tested the hypothesis that oxytocin (OT) contracts blood vessels via vasopressin V1A (VP) receptors, and that this depends on pregnancy. STUDY DESIGN Concentration-contraction relationships (CCR) to OT and VP (10(-12)-10(-6) mol/L) were obtained in different blood vessels. CCR were obtained in uterine arteries (UA) from nonpregnant, mid-pregnant, and late pregnant rats (n = 6-10 per group) in the absence and presence of selective antagonists (10(-7) mol/L). RESULTS Sensitivity to OT, but not to VP, is attenuated in pregnant rat UA. Antagonists shifted CCR of OT and VP to the right, and, to a lesser extent, of the counterpart, in all UA. VP antagonist depresses oxytocin CCR much more than OT antagonist in pregnant rat UA. CONCLUSION OT and VP contract UA via their own receptors, although partial cross-activation is evident. Adaptation to pregnancy led to attenuated sensitivity of UA smooth muscle to OT and transformed OT receptors into VP-like ones.
Collapse
MESH Headings
- Adaptation, Physiological
- Animals
- Antidiuretic Hormone Receptor Antagonists
- Aorta, Thoracic/drug effects
- Arginine Vasopressin/analogs & derivatives
- Arginine Vasopressin/pharmacology
- Arteries/drug effects
- Arteries/metabolism
- Computer Systems
- Dose-Response Relationship, Drug
- Female
- Femoral Artery/drug effects
- Muscle, Smooth, Vascular/drug effects
- Osmolar Concentration
- Oxytocics/administration & dosage
- Oxytocics/pharmacology
- Oxytocin/administration & dosage
- Oxytocin/analogs & derivatives
- Oxytocin/pharmacology
- Pregnancy
- RNA, Messenger/metabolism
- Rats
- Rats, Sprague-Dawley
- Receptors, Oxytocin/antagonists & inhibitors
- Receptors, Oxytocin/genetics
- Receptors, Vasopressin/genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Uterus/blood supply
- Vasoconstriction
- Vasopressins/administration & dosage
- Vasopressins/antagonists & inhibitors
- Vasopressins/pharmacology
Collapse
Affiliation(s)
- Yuri P Vedernikov
- Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA
| | | | | | | | | |
Collapse
|
24
|
Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M. Position 4 analogues of [deamino-Cys1] arginine vasopressin exhibit striking species differences for human and rat V2/V1b receptor selectivity. J Pept Sci 2006; 12:190-8. [PMID: 16130178 DOI: 10.1002/psc.710] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Arginine vasopressin (AVP) mediates a wide variety of biological actions by acting on three distinct G-protein coupled receptors, termed V(1a) (vascular), V(1b) (pituitary) and V(2) (renal). It also binds to the oxytocin (OT) receptor. As part of a program aimed at the design of selective agonists for the human V(1b) receptor, we recently reported the human V(1b), V(1a), V(2) and OT receptor affinities of the following position 4 substituted analogues of [deamino-Cys(1)] arginine vasopressin (dAVP)-(1) d[Leu(4)]AVP, (2) d[Orn(4)]AVP, (3) d[Lys(4)]AVP, (4) d[Har(4)]AVP, (5) d[Arg(4)]AVP, (6) d[Val(4)]AVP, (7) d[Ala(4)]AVP, (8) d[Abu(4)]AVP, (9) d[Nva(4)]AVP, (10) d[Nle(4)]AVP, (11) d[Ile(4)]AVP, (12) d[Phe(4)]AVP, (13) d[Asn(4)]AVP, (14) d[Thr(4)]AVP: (15) d[Dap(4)]AVP. With the exception of Nos. 7 and 12, all peptides exhibit very high affinities for the human V(1b) receptor. Furthermore, peptides 1-4 exhibit high selectivities for the human V(1b) receptor with respect to the V(1a), V(2) and OT receptors and, with d[Cha(4)]AVP, in functional tests, are the first high affinity selective agonists for the human V(1b) receptor (Cheng LL et al., J. Med. Chem. 47: 2375-2388, 2004). We report here the pharmacological properties of peptides 1-4, 5 (from a resynthesis), 7, 9-13, 15 in rat bioassays (antidiuretic, vasopressor and oxytocic) (in vitro: no Mg(++)) with those previously reported for peptides 5, 6, 8, 14. We also report the rat V(1b), V(1a), V(2) and OT receptor affinities of peptides 1-5 and the rat V(2) receptor affinities for peptides: 7-15.The antidiuretic activities in units/mg of peptides 1-15, are: 1=378; 2=260; 3=35; 4=505; 5=748; 6=1150; 7=841; 8=1020; 9=877; 10=1141; 11=819, 12=110; 13=996; 14=758; 15=1053. Peptides 1-4 exhibit respectively the following rat and human (in brackets) V(2) receptor affinities: 1=3.1 nm (245 nm); 2=3.4 nm (1125 nm); 3=24.6 nm (11,170 nm); 4=0.6 nm (1386 nm). Their rat V(1b) receptor affinities are 1=0.02 nm; 2=0.45 nm; 3=9.8 nm; 4=0.32 nm. Their rat V(1a) receptor affinities are 1=1252 nm; 2=900 nm; 3=1478 nm; 4=32 nm. Their rat oxytocin (OT) receptor affinities are 1=481 nm; 2=997 nm; 3=5042 nm; 4=2996 nm. All four peptides have high affinities and selectivities for the rat V(1b) receptor with respect to the rat V(1a) and OT receptors. However, in contrast to their high selectivity for the human V(1b) receptor with respect to the human V(2) receptor, they are not selective for the V(1b) receptor with respect to the V(2) receptor in the rat. These findings confirm previous observations of profound species differences between the rat and human V(2) receptors. Peptides 1-4 are promising leads to the design of the first high affinity selective agonists for the rat V(1b) receptor.
Collapse
Affiliation(s)
- Gilles Guillon
- Institut de Génomique Fonctionnelle, UMR5203-CNRS, U661-INSERM, Université Montpellier I & II, 141 rue de la Cardonille, 34094 Montpellier Cedex 5, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Saavedra JM, Pavel J. Angiotensin II AT1 receptor antagonists inhibit the angiotensin-CRF-AVP axis and are potentially useful for the treatment of stress-related and mood disorders. Drug Dev Res 2005. [DOI: 10.1002/ddr.20027] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|